Last reviewed · How we verify
GSK3074477 FDC - 1 — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GSK3074477 FDC - 1 (GSK3074477 FDC - 1) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GSK3074477 FDC - 1 TARGET | GSK3074477 FDC - 1 | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GSK3074477 FDC - 1 CI watch — RSS
- GSK3074477 FDC - 1 CI watch — Atom
- GSK3074477 FDC - 1 CI watch — JSON
- GSK3074477 FDC - 1 alone — RSS
Cite this brief
Drug Landscape (2026). GSK3074477 FDC - 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk3074477-fdc-1. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab